2-Amino-3-tert-butyl-5-[1,1,1,3,3,3-hexadeuterio-2-(trideuteriomethyl)propan-2-yl]phenol

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-Amino-3-tert-butyl-5-[1,1,1,3,3,3-hexadeuterio-2-(trideuteriomethyl)propan-2-yl]phenol
• 英文别名: 2-amino-3-tert-butyl-5-[1,1,1,3,3,3-hexadeuterio-2-(trideuteriomethyl)propan-2-yl]phenol
• 化学式: C14H23NO
• 分子量: 230.39
• InChiKey: CLRBDDUMPXYLHE-GQALSZNTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• [EN] METHODS OF TREATMENT FOR CYSTIC FIBROSIS<br/>[FR] MÉTHODES DE TRAITEMENT DE LA FIBROSE KYSTIQUE
  申请人：VERTEX PHARMA

  公开号：WO2019018395A1

  公开（公告）日：2019-01-24

  Compound I of the formula (I) and/or pharmaceutically acceptable salt(s) of Compound I comprised in a pharmaceutical composition and methods of using the same to treat cystic fibrosis.

  化合物I的公式(I)和/或化合物I的药用盐所包含在一种药物组合物中，以及使用这种药物组合物治疗囊性纤维化的方法。
• Deuterated CFTR potentiators
  申请人：Vertex Pharmaceuticals (Europe) Limited

  公开号：US10479766B2

  公开（公告）日：2019-11-19

  This invention relates to compounds of Formula I: and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator.

  本发明涉及式 I 的化合物： 及其药学上可接受的盐类。本发明还提供了包含本发明化合物的组合物，以及这种组合物在治疗疾病和病症的方法中的用途，这些疾病和病症可通过施用 CFTR 增效剂得到有益的治疗。
• Methods of treatment for cystic fibrosis
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US11253509B2

  公开（公告）日：2022-02-22

  Compound I of the formula (formula) A pharmaceutically acceptable salt of Compound I. Pharmaceutical compositions containing at least Compound I and methods of treating cystic fibrosis comprising administering at least Compound I. Pharmaceutical compositions containing a pharmaceutically acceptable salt of at least Compound I and methods of treating cystic fibrosis comprising administering a pharmaceutically acceptable salt of at least Compound I.

  含有至少化合物 I 的药学上可接受的盐的药用组合物和治疗囊性纤维化的方法，包括施用至少化合物 I 的药学上可接受的盐。
• METHODS OF TREATMENT FOR CYSTIC FIBROSIS
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：EP3634402A1

  公开（公告）日：2020-04-15
• DEUTERATED CFTR POTENTIATORS
  申请人：Morgan Adam J.

  公开号：US20140073667A1

  公开（公告）日：2014-03-13

  This invention relates to compounds of Formula I: and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator.